

Q-linea - Greater expectations for long term market share

Redeye raises Q-linea's fair value based on a stronger belief in the strength of the Thermo Fisher deal than previously expected and execution according to plan. We have also lowered our required rate of return. (WACC to 10% vs 12% previously). The company has a very exciting year ahead with the upcoming prospective study during H2 this year and the process for CE-IVD approval to be able to launch ASTar on the market during 2021. Our new motivated value in the base case is SEK 175 (SEK 87).

Read more and download the Research Update

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

Q-linea - Greater expectations for long term market share